Theranostics 2019; 9(23):6780-6796. doi:10.7150/thno.37123 This issue Cite

Research Paper

Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy

Wenquan Ou1, Jeong Hoon Byeon2✉, Zar Chi Soe1, Bo Kyun Kim1, Raj Kumar Thapa1, Biki Gupta1, Bijay Kumar Poudel1, Sae Kwang Ku3, Chul Soon Yong1, Jong Oh Kim1✉

1. College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
2. School of Mechanical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.
3. College of Korean Medicine, Daegu Haany University, Gyeongsan 38610, Republic of Korea.

Citation:
Ou W, Byeon JH, Soe ZC, Kim BK, Thapa RK, Gupta B, Poudel BK, Ku SK, Yong CS, Kim JO. Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy. Theranostics 2019; 9(23):6780-6796. doi:10.7150/thno.37123. https://www.thno.org/v09p6780.htm
Other styles

File import instruction

Abstract

Graphic abstract

Several therapeutic nanosystems have been engineered to remedy the shortcomings of cancer monotherapies, including immunotherapy (stimulating the host immune system to eradicate cancer), to improve therapeutic efficacy with minimizing off-target effects and tumor-induced immunosuppression. Light-activated components in nanosystems confer additional phototherapeutic effects as combinatorial modalities; however, systemic and thermal toxicities with unfavorable accumulation and excretion of nanoystem components now hamper their practical applications. Thus, there remains a need for optimal multifunctional nanosystems to enhance targeted, durable, and mild combination therapies for efficient cancer treatment without notable side effects.

Methods: A nanosystem constructed with a base core (poly-L-histidine [H]-grafted black phosphorus [BP]) and a shell (erythrocyte membrane [EM]) is developed to offer a mild photoresponsive (near-infrared) activity with erythrocyte mimicry. In-flight electrostatic tailoring to extract uniform BP nanoparticles maintains a hydrodynamic size of <200 nm (enabling enhanced permeability and retention) after EM cloaking and enhances their biocompatibility.

Results: Ephrin-A2 receptor-specific peptide (YSA, targeting cancer cells), interleukin-1α silencing small interfering RNA (ILsi, restricting regulatory T cell trafficking), and paclitaxel (X, inducing durable chemotherapeutics) are incorporated within the base core@shell constructs to create BP-H-ILsi-X@EM-YSA architectures, which provide a more intelligent nanosystem for combination cancer therapies.

Conclusion: The in-flight tailoring of BP particles provides a promising base core for fabricating <200 nm EM-mimicking multifunctional nanosystems, which could be beneficial for constructing smarter nanoarchitectures to use in combination cancer therapies.

Keywords: therapeutic nanosystems, tailored black phosphorus nanoparticles, erythrocyte membranes, core@shell constructs, combination cancer therapies.


Citation styles

APA
Ou, W., Byeon, J.H., Soe, Z.C., Kim, B.K., Thapa, R.K., Gupta, B., Poudel, B.K., Ku, S.K., Yong, C.S., Kim, J.O. (2019). Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy. Theranostics, 9(23), 6780-6796. https://doi.org/10.7150/thno.37123.

ACS
Ou, W.; Byeon, J.H.; Soe, Z.C.; Kim, B.K.; Thapa, R.K.; Gupta, B.; Poudel, B.K.; Ku, S.K.; Yong, C.S.; Kim, J.O. Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy. Theranostics 2019, 9 (23), 6780-6796. DOI: 10.7150/thno.37123.

NLM
Ou W, Byeon JH, Soe ZC, Kim BK, Thapa RK, Gupta B, Poudel BK, Ku SK, Yong CS, Kim JO. Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy. Theranostics 2019; 9(23):6780-6796. doi:10.7150/thno.37123. https://www.thno.org/v09p6780.htm

CSE
Ou W, Byeon JH, Soe ZC, Kim BK, Thapa RK, Gupta B, Poudel BK, Ku SK, Yong CS, Kim JO. 2019. Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy. Theranostics. 9(23):6780-6796.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image